AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$CRSP

CRISPR Therapeutics AG

Price · $CRSPvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $CRSP in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $CRSP in the last 30 days.

Top stories · $CRSPMore →
MAY 14·AD HOC NEWSMed

CRISPR Therapeutics stock (CH0334081137): Bernstein raises price target amid gene-editing momentum

Bernstein has raised its price target for CRISPR Therapeutics (CH0334081137) to $56, maintaining its rating and reflecting confidence in the gene-editing platform developer's therapeutic pipeline. CRISPR Therapeutics, specializing in CRISPR/Cas9 gene-editing therapies, is watched by investors for its potential in precision medicine, with its financial trajectory dependent on advancing candidates through regulatory approval and commercialization. The company's stock traded at $52.75 USD on May 14, 2026, on Nasdaq.

APR 10·openPR.com

Biomedical Crispr Gene Editing Market Set to Boom Rapidly,

Coherent Market Insights has released a comprehensive report on the Biomedical CRISPR Gene Editing Market, forecasting strong growth through 2033. The report analyzes market trends, competitive dynamics, regional performance, and growth potential, making it a valuable tool for business leaders. Key market players like CRISPR Therapeutics, Intellia Therapeutics, and Editas Medicine are highlighted, and the report provides insights into segmentation, research methodology, and strategic recommendations.

APR 5·Yahoo Finance Singapore

CRISPR Therapeutics AG (CRSP) stock price, news, quote and history

This page provides comprehensive information on CRISPR Therapeutics AG (CRSP), a gene-editing company. It includes real-time stock price data, historical performance, key financial metrics, analyst insights, and comparisons with similar biotechnology firms. The company specializes in gene-based medicines using its CRISPR/Cas9 platform, with lead product CASGEVY for blood disorders and various CAR T-cell therapies in development.

News on $CRSP

All news →